To recover your password please fill in your email address
Please fill in below form to create an account with us
A Randomised Phase II Study Of nab-paclitaxel In Combination With Carboplatin As First Line Treatment Of Gastrointestinal Neuroendocrine Carcinomas
See ANZCTR for full trial details >
Trial Summary: |
To establish if carboplatin and nab-paclitaxel combination is an effective and tolerable chemotherapy treatment for grade 3 advanced gastrointestinal NECs. To explore translational biologic, molecular and functional imaging endpoints to inform future research and improve outcomes for NEC patients. |
Supported By: |
Specialised Therapeutics Australia (STA), AGITG and the NHMRC. |
Eligibility: |
Adults with histologically confirmed advanced and/or metastatic, WHO ENET Grade 3, unresectable gastrointestinal NECs, including both small cell and large cell-NEC. |
Registration ID: |
ACTRN12616000958482 |
Participation: |
Australia |
Australian Lead Group: |
AGITG |
Status: |
Closed |
Activation Date: |
15/09/2016 |
Chairs: |
Dr Lorraine Chantrill |
Contact: |